Zhijian Wu
About Zhijian Wu
Zhijian Wu is a Staff Scientist at the National Institutes of Health, where he has worked since 2009. He has a background in philosophy and has held various positions in ocular gene therapy at the National Eye Institute.
Work at National Institutes of Health
Zhijian Wu has been employed at the National Institutes of Health (NIH) since 2009, serving as a Staff Scientist. His role involves conducting advanced research in the field of ocular gene therapy. Wu's work contributes to the NIH's mission to enhance health, lengthen life, and reduce illness and disability. He has been instrumental in developing innovative approaches to treat eye diseases.
Current Role at National Eye Institute
Since 2014, Zhijian Wu has held the position of Head of the Ocular Gene Therapy Core at the National Eye Institute (NEI) in Bethesda, Maryland. In this capacity, he oversees projects focused on gene therapy techniques aimed at addressing various ocular conditions. His leadership in this role has been significant in advancing the NEI's research initiatives.
Previous Experience at National Eye Institute
Before becoming the Head of the Ocular Gene Therapy Core, Zhijian Wu served as the Acting Head of the same core from 2013 to 2014. During this period, he contributed to the development and implementation of gene therapy projects, enhancing the NEI's research capabilities in ocular health.
Education and Expertise
Zhijian Wu studied at the Chinese Academy of Preventive Medicine, now known as the China CDC, where he earned his Doctorate in Philosophy from 1997 to 2000. His educational background provides a strong foundation for his research in gene therapy and ocular health, equipping him with the necessary skills to contribute to scientific advancements in these fields.
Postdoctoral Research Experience
Prior to his tenure at the NIH, Zhijian Wu worked as a Postdoctoral researcher at the University of North Carolina at Chapel Hill from 2002 to 2006. This experience allowed him to develop his research skills and focus on ocular gene therapy, laying the groundwork for his future roles in the field.